Article
Santa Barbara, Calif. - Inamed Corporation and its partner Ipsen,a European pharmaceutical company, reported results of a Phase II dosingstudy of their botulinum toxin type A product yesterday at the AAD meeting.
Day 1 Recap: SBS 2025
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Beyond Topicals: Surgical Solutions for Vitiligo
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Balancing Adolescent Acne Treatment and Well-being
The Future of Pediatric Care at MOPD